
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1205587/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis and Rheumatism, 2010, 62, 2569-2581.	6.7	6,781
2	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases, 2017, 76, 960-977.	0.9	3,366
3	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 2010, 69, 1580-1588.	0.9	2,994
4	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the Rheumatic Diseases, 2020, 79, 685-699.	0.9	1,860
5	Treating rheumatoid arthritis to target: recommendations of an international task force. Annals of the Rheumatic Diseases, 2010, 69, 631-637.	0.9	1,711
6	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Annals of the Rheumatic Diseases, 2014, 73, 492-509.	0.9	1,688
7	Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, doubleâ€blind, placeboâ€controlled, phase III trial evaluating primary efficacy and safety at twentyâ€four weeks. Arthritis and Rheumatism, 2006, 54, 2793-2806.	6.7	1,462
8	Rheumatoid arthritis. Nature Reviews Disease Primers, 2018, 4, 18001.	30.5	1,441
9	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases, 2010, 69, 964-975.	0.9	1,429
10	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Annals of the Rheumatic Diseases, 2016, 75, 3-15.	0.9	1,114
11	Novel treatment strategies in rheumatoid arthritis. Lancet, The, 2017, 389, 2338-2348.	13.7	697
12	Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet, The, 2013, 381, 451-460.	13.7	610
13	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Annals of the Rheumatic Diseases, 2020, 79, 700.1-712.	0.9	609
14	Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Annals of the Rheumatic Diseases, 2013, 72, 517-524.	0.9	484
15	Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, 909-920.	0.9	394
16	The etiology of rheumatoid arthritis. Journal of Autoimmunity, 2020, 110, 102400.	6.5	362
17	Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet, The, 2017, 389, 2317-2327.	13.7	316
18	Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis?. Arthritis and Rheumatism, 1997, 40, 5-18.	6.7	306

2

#	Article	IF	CITATIONS
19	Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet, The, 2018, 391, 2503-2512.	13.7	280
20	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1101-1136.	0.9	277
21	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Annals of the Rheumatic Diseases, 2016, 75, 16-22.	0.9	275
22	Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood, 2009, 113, 214-223.	1.4	269
23	Emerging cell and cytokine targets in rheumatoid arthritis. Nature Reviews Rheumatology, 2014, 10, 77-88.	8.0	260
24	Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Annals of the Rheumatic Diseases, 2017, 76, 840-847.	0.9	244
25	Preactivated Peripheral Blood Monocytes in Patients With Essential Hypertension. Hypertension, 1999, 34, 113-117.	2.7	239
26	Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis and Rheumatism, 1991, 34, 129-140.	6.7	234
27	Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Science Immunology, 2021, 6, eabj1031.	11.9	223
28	Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Annals of the Rheumatic Diseases, 2015, 74, 415-421.	0.9	217
29	A new hypothesis of modular glucocorticoid actions: Steroid treatment of rheumatic diseases revisited. Arthritis and Rheumatism, 1998, 41, 761-767.	6.7	209
30	A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Annals of the Rheumatic Diseases, 2014, 73, 69-74.	0.9	208
31	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2020, 79, 760-770.	0.9	205
32	EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Annals of the Rheumatic Diseases, 2020, 79, 851-858.	0.9	204
33	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Annals of the Rheumatic Diseases, 2010, 69, 638-643.	0.9	203
34	Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24â€months, with a 12-month, double-blind treatment period. Annals of the Rheumatic Diseases, 2015, 74, 19-26.	0.9	201
35	Rheumatoid factor revisited. Current Opinion in Rheumatology, 2004, 16, 246-253.	4.3	193
36	Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Annals of the Rheumatic Diseases, 2015, 74, 1037-1044.	0.9	190

#	Article	IF	CITATIONS
37	Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus. New England Journal of Medicine, 2020, 383, 1149-1155.	27.0	178
38	Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Annals of the Rheumatic Diseases, 2007, 66, 732-739.	0.9	175
39	Efficacy and Safety of ABTâ€494, a Selective JAKâ€1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate. Arthritis and Rheumatology, 2016, 68, 2857-2866.	5.6	172
40	Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2020, 79, 744-759.	0.9	167
41	Nucleosomes are major T and B cell autoantigens in systemic lupus erythematosus. Arthritis and Rheumatism, 2000, 43, 2307-2315.	6.7	164
42	Sialic acid–binding Igâ€like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis and Rheumatism, 2008, 58, 1136-1145.	6.7	163
43	Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain lowresults from RABBIT, the German biologics register. Arthritis Research and Therapy, 2006, 8, R66.	3.5	160
44	The changing landscape of biosimilars in rheumatology. Annals of the Rheumatic Diseases, 2016, 75, 974-982.	0.9	160
45	Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Annals of the Rheumatic Diseases, 2016, 75, 1081-1091.	0.9	152
46	The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2008, 10, R67.	3.5	150
47	Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 1445-1452.	0.9	149
48	The stress protein BiP is overexpressed and is a major B and T cell target in rheumatoid arthritis. Arthritis and Rheumatism, 2001, 44, 761-771.	6.7	147
49	Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Annals of the Rheumatic Diseases, 2011, 70, 755-759.	0.9	146
50	Sarilumab and Nonbiologic Diseaseâ€Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. Arthritis and Rheumatology, 2017, 69, 277-290.	5.6	146
51	Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet, The, 2016, 388, 2763-2774.	13.7	144
52	Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis. Arthritis and Rheumatology, 2019, 71, 1042-1055.	5.6	135
53	The role of B cells in rheumatoid arthritis. Current Opinion in Rheumatology, 2003, 15, 246-252.	4.3	133
54	Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1102-1107.	0.9	131

#	Article	IF	CITATIONS
55	Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Annals of the Rheumatic Diseases, 2022, 81, 695-709.	0.9	130
56	Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Annals of the Rheumatic Diseases, 2021, 80, 304-311.	0.9	129
57	A randomised phase IIb study of mavrilimumab, a novel GM–CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1020-1030.	0.9	117
58	Managing rheumatic and musculoskeletal diseases — past, present and future. Nature Reviews Rheumatology, 2017, 13, 443-448.	8.0	117
59	Inflammation assessment in patients with arthritis using a novel in vivo fluorescence optical imaging technology. Annals of the Rheumatic Diseases, 2012, 71, 504-510.	0.9	116
60	IFNα and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2013, 72, 1639-1645.	0.9	115
61	Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-Â, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study. Annals of the Rheumatic Diseases, 2011, 70, 1542-1549.	0.9	109
62	Autologous stem-cell transplantation in refractory autoimmune diseases after in vivo immunoablation and ex vivo depletion of mononuclear cells. Arthritis Research, 2000, 2, 327-36.	2.0	103
63	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Annals of the Rheumatic Diseases, 2013, 72, 482-492.	0.9	102
64	Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA). Annals of the Rheumatic Diseases, 2016, 75, 68-74.	0.9	100
65	Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 414-417.	0.9	94
66	Systemic sclerosis: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000782.	3.8	91
67	Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, openâ€label, twelveâ€week study. Arthritis and Rheumatism, 2008, 59, 32-41.	6.7	89
68	EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. Annals of the Rheumatic Diseases, 2022, 81, 1628-1639.	0.9	89
69	Differential expression of cathepsins B and L compared with matrix metalloproteinases and their respective inhibitors in rheumatoid arthritis and osteoarthritis: A parallel investigation by semiquantitative reverse transcriptase-polymerase chain reaction and immunohistochemistry. Arthritis and Rheumatism, 1998, 41, 1378-1387.	6.7	86
70	The immunologic homunculus in rheumatoid arthritis. Arthritis and Rheumatism, 1999, 42, 2499-2506.	6.7	81
71	Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Annals of the Rheumatic Diseases, 2013, 72, 583-589.	0.9	80
72	An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clinical Rheumatology, 2008, 27, 1021-1028.	2.2	78

#	Article	IF	CITATIONS
73	Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. Arthritis Research and Therapy, 2009, 11, R170.	3.5	78
74	Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. Lancet, The, 2020, 396, 267-276.	13.7	78
75	The US7 score is sensitive to change in a large cohort of patients with rheumatoid arthritis over 12â€months of therapy. Annals of the Rheumatic Diseases, 2013, 72, 1163-1169.	0.9	77
76	Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1078-1085.	0.9	76
77	A Randomized Phase <scp>II</scp> b Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 49-59.	5.6	76
78	Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Annals of the Rheumatic Diseases, 2021, 80, 727-738.	0.9	76
79	Mavrilimumab, a Fully Human Granulocyte–Macrophage Colony‧timulating Factor Receptor α Monoclonal Antibody. Arthritis and Rheumatology, 2018, 70, 679-689.	5.6	73
80	EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases. RMD Open, 2019, 5, e001014.	3.8	73
81	The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Annals of the Rheumatic Diseases, 2011, 70, 818-822.	0.9	72
82	Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. Annals of the Rheumatic Diseases, 2011, 70, 1999-2002.	0.9	71
83	Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Annals of the Rheumatic Diseases, 2022, 81, 335-343.	0.9	71
84	Bioenergetics of Human Peripheral Blood Mononuclear Cell Metabolism in Quiescent, Activated, and Glucocorticoid-Treated States. Bioscience Reports, 2000, 20, 289-302.	2.4	70
85	Systemic lupus erythematosus: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000793.	3.8	66
86	Cis - and Trans -Acting Gene Regulation Is Associated with Osteoarthritis. American Journal of Human Genetics, 2006, 78, 793-803.	6.2	64
87	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019. Annals of the Rheumatic Diseases, 2020, 79, 88-93.	0.9	63
88	Indocyanine Green–Enhanced Fluorescence Optical Imaging in Patients With Early and Very Early Arthritis: A Comparative Study With Magnetic Resonance Imaging. Arthritis and Rheumatism, 2013, 65, 3036-3044.	6.7	62
89	Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases, 2016, 75, 1293-1301.	0.9	61
90	Urinary CD4 T cells identify SLE patients with proliferative lupus nephritis and can be used to monitor treatment response. Annals of the Rheumatic Diseases, 2014, 73, 277-283.	0.9	60

#	Article	IF	CITATIONS
91	Monocyte alterations in rheumatoid arthritis are dominated by preterm release from bone marrow and prominent triggering in the joint. Annals of the Rheumatic Diseases, 2018, 77, 300-308.	0.9	59
92	EULAR points to consider for the use of big data in rheumatic and musculoskeletal diseases. Annals of the Rheumatic Diseases, 2020, 79, 69-76.	0.9	55
93	B Cell Numbers Predict Humoral and Cellular Response Upon <scp>SARS</scp> – <scp>CoV</scp> â€2 Vaccination Among Patients Treated With Rituximab. Arthritis and Rheumatology, 2022, 74, 934-947.	5.6	55
94	Carbamylation of vimentin is inducible by smoking and represents an independent autoantigen in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1176-1183.	0.9	54
95	Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis. Advances in Therapy, 2020, 37, 364-380.	2.9	51
96	Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. Lancet Rheumatology, The, 2020, 2, e347-e357.	3.9	51
97	Tofacitinib With Methotrexate in Thirdâ€Line Treatment of Patients With Active Rheumatoid Arthritis: Patientâ€Reported Outcomes From a Phase III Trial. Arthritis Care and Research, 2015, 67, 475-483.	3.4	50
98	Successful treatment of patients with systemic lupus erythematosus by immunoadsorption with a C1q column: A pilot study. Arthritis and Rheumatism, 2001, 44, 1962-1963.	6.7	49
99	Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study. Rheumatology, 2017, 56, 1618-1626.	1.9	49
100	The cellular signature of urinary immune cells in Lupus nephritis: new insights into potential biomarkers. Arthritis Research and Therapy, 2015, 17, 94.	3.5	48
101	Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. RMD Open, 2020, 6, e001095.	3.8	48
102	Rheumatology 4.0: big data, wearables and diagnosis by computer. Annals of the Rheumatic Diseases, 2018, 77, 963-965.	0.9	47
103	Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials. Arthritis Care and Research, 2019, 71, 367-378.	3.4	47
104	Gene Expression Profiling of Rheumatoid Arthritis Synovial Cells Treated with Antirheumatic Drugs. Journal of Biomolecular Screening, 2007, 12, 328-340.	2.6	46
105	A Pronounced Inflammatory Activity Characterizes the Early Fracture Healing Phase in Immunologically Restricted Patients. International Journal of Molecular Sciences, 2017, 18, 583.	4.1	45
106	Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. BMC Musculoskeletal Disorders, 2014, 15, 14.	1.9	44
107	Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis. Arthritis Research and Therapy, 2018, 20, 52.	3.5	44
108	High maternal expression of SIGLEC1 on monocytes as a surrogate marker of a type I interferon signature is a risk factor for the development of autoimmune congenital heart block. Annals of the Rheumatic Diseases, 2017, 76, 1476-1480.	0.9	43

#	Article	IF	CITATIONS
109	Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up. Rheumatology, 2020, 59, 292-302.	1.9	43
110	Effects of 60-day bed rest with and without exercise on cellular and humoral immunological parameters. Cellular and Molecular Immunology, 2015, 12, 483-492.	10.5	42
111	SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndrome. RMD Open, 2016, 2, e000292.	3.8	42
112	Association of <i>HLA-DRB1</i> alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis. Rheumatology, 2016, 55, 49-55.	1.9	40
113	Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. Annals of the Rheumatic Diseases, 2022, 81, 184-192.	0.9	40
114	Antiphospholipid antibody profiling — Time for a new technical approach?. Autoimmunity Reviews, 2012, 11, 821-826.	5.8	39
115	Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register. Annals of the Rheumatic Diseases, 2022, 81, 41-47.	0.9	39
116	Antiphospholipid syndrome: state of the art on clinical practice guidelines. RMD Open, 2018, 4, e000785.	3.8	38
117	EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. Annals of the Rheumatic Diseases, 2021, 80, 698-706.	0.9	37
118	Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study. BMC Musculoskeletal Disorders, 2015, 16, 176.	1.9	36
119	ROUTINE—a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany. Rheumatology, 2016, 55, 624-635.	1.9	35
120	Single-step autoantibody profiling in antiphospholipid syndrome using a multi-line dot assay. Arthritis Research and Therapy, 2011, 13, R118.	3.5	34
121	Detection of severe digital vasculopathy in systemic sclerosis by colour Doppler sonography is associated with digital ulcers. Rheumatology, 2017, 56, 1865-1873.	1.9	33
122	Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases. Annals of the Rheumatic Diseases, 2022, 81, 881-888.	0.9	33
123	Evidence for the separate molecular expression of four distinct polymorphic Ia epitopes on cells of DR4 homozygous individuals. Human Immunology, 1984, 10, 69-81.	2.4	32
124	Near-infrared Fluorescence Optical Imaging in Early Rheumatoid Arthritis: A Comparison to Magnetic Resonance Imaging and Ultrasonography. Journal of Rheumatology, 2015, 42, 1112-1118.	2.0	32
125	Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2018, 20, 129.	3.5	31
126	Current status of use of big data and artificial intelligence in RMDs: a systematic literature review informing EULAR recommendations. RMD Open, 2019, 5, e001004.	3.8	30

e001595.	0.8	30 30
128Targeting GM-CSF in rheumatoid arthritis. Clinical and Experimental Rheumatology, 2016, 34, 39-44.0		30
Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR). Annals of the Rheumatic Diseases. 2018. 77. annrheumdis-2017-212565.	0.9	29
An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data. Drug Safety, 2020, 43, 379-392.	3.2	28
 Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program. Drug Safety, 2021, 44, 515-530. 	3.2	28
Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany. BMJ Open, 2018, 8, e021082.	1.9	28
Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study. Arthritis Research and Therapy, 2014, 3. 16, R24.	3.5	27
Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment. RMD Open, 2019, 5, e000887.	3.8	27
¹³⁵ Understanding the patient perspective - results of the Rheumatoid Arthritis: Insights, Strategies & o Expectations (RAISE) patient needs survey. Clinical and Experimental Rheumatology, 2013, 31, 350-7.	0.8	27
 Patient-tailored therapy in rheumatoid arthritis: an editorial review. Current Opinion in Rheumatology, 2010, 22, 237-245. 	4.3	26
¹³⁷ Impact of the CTLAâ \in 4/CD28 axis on the processes of joint inflammation in rheumatoid arthritis. Arthritis and Rheumatism, 2013, 65, 81-87.	6.7	26
Mapping urinary chemokines in human lupus nephritis: Potentially redundant pathways recruit CD4 ⁺ and CD8 ⁺ T cells and macrophages. European Journal of Immunology, 2 2017, 47, 180-192.	2.9	26
 IL-2 Therapy Diminishes Renal Inflammation and the Activity of Kidney-Infiltrating CD4+ T Cells in Murine Lupus Nephritis. Cells, 2019, 8, 1234. 	4.1	26
Pathogenic memory plasma cells in autoimmunity. Current Opinion in Immunology, 2019, 61, 86-91. 5.	5.5	26
 Nuclear antigen–reactive CD4+ T cells expand in active systemic lupus erythematosus, produce effector cytokines, and invade the kidneys. Kidney International, 2021, 99, 238-246. 	5.2	26
 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. Annals of the Rheumatic Diseases, 2022, 81, 34-40. 	0.9	26
Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study 143 TAMARA as an example and their comparison with traditional remission criteria. Annals of the 0 Rheumatic Diseases, 2011, 70, 1986-1990.	0.9	25

Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands (OA) Tj ETQq0 0 0 rgBT $\frac{10}{1.6}$ Tf 50 62

#	Article	IF	CITATIONS
145	Increased Periodontal Attachment Loss in Patients With Systemic Sclerosis. Journal of Periodontology, 2016, 87, 763-771.	3.4	25
146	Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease. Annals of the Rheumatic Diseases, 2022, 81, 1313-1322.	0.9	25
147	Synovial tissue transcriptomes of long-standing rheumatoid arthritis are dominated by activated macrophages that reflect microbial stimulation. Scientific Reports, 2020, 10, 7907.	3.3	24
148	Carbamylated vimentin represents a relevant autoantigen in Latin American (Cuban) rheumatoid arthritis patients. Rheumatology International, 2016, 36, 781-791.	3.0	23
149	Immunoglobulin V? light chain gene usage in patients with Sj�gren's syndrome. Arthritis and Rheumatism, 2001, 44, 2620-2632.	6.7	22
150	Common Language Description of the Term Rheumatic and Musculoskeletal Diseases (<scp>RMD</scp> s) for Use in Communication With the Lay Public, Healthcare Providers, and Other Stakeholders Endorsed by the European League Against Rheumatism (<scp>EULAR</scp>) and the American College of Rheumatology (<scp>ACR</scp>). Arthritis and Rheumatology, 2018, 70, 826-831.	5.6	21
151	IgG4-related diseases: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000787.	3.8	21
152	Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies. Arthritis Research and Therapy, 2020, 22, 139.	3.5	21
153	Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response. Annals of the Rheumatic Diseases, 2021, 80, 1361-1362.	0.9	21
154	Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing. International Journal of Molecular Sciences, 2020, 21, 865.	4.1	21
155	Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials. Arthritis Research and Therapy, 2020, 22, 206.	3.5	20
156	Type I interferon as a biomarker in autoimmunity and viral infection: a leukocyte subset-specific analysis unveils hidden diagnostic options. Journal of Molecular Medicine, 2017, 95, 753-765.	3.9	19
157	Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000784.	3.8	19
158	Systemic sclerosis-associated myositis features minimal inflammation and characteristic capillary pathology. Acta Neuropathologica, 2021, 141, 917-927.	7.7	19
159	Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands: results of the OA-TREAT study—a randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. RMD Open, 2021, 7, e001660.	3.8	19
160	sE-selectin for stratifying outcome in rheumatoid arthritis. Arthritis and Rheumatism, 2003, 49, 546-548.	6.7	18
161	Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies. Journal of Rheumatology, 2018, 45, 177-187.	2.0	18
162	Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. Arthritis Research and Therapy, 2018, 20, 174.	3.5	18

#	Article	IF	CITATIONS
163	Peripheral blood mononuclear cells are hypomethylated in active rheumatoid arthritis and methylation correlates with disease activity. Rheumatology, 2021, 60, 1984-1995.	1.9	18
164	A broad look into the future of rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210762.	2.7	18
165	What is the clinical significance of anti-Sm antibodies in systemic lupus erythematosus? A comparison with anti-dsDNA antibodies and C3. Clinical and Experimental Rheumatology, 2017, 35, 598-606.	0.8	18
166	Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials. Rheumatology and Therapy, 2022, 9, 521-539.	2.3	18
167	Disturbed microcirculation in the hands of patients with systemic sclerosis detected by fluorescence optical imaging: a pilot study. Arthritis Research and Therapy, 2017, 19, 87.	3.5	17
168	Digital crowdsourcing: unleashing its power in rheumatology. Annals of the Rheumatic Diseases, 2020, 79, 1139-1140.	0.9	17
169	Smart battles: immunosuppression versus immunomodulation in the inflammatory RMDs. Annals of the Rheumatic Diseases, 2020, 79, 991-993.	0.9	17
170	Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany. Rheumatology International, 2019, 39, 131-140.	3.0	16
171	Adherence to Treat-to-target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort. Journal of Rheumatology, 2020, 47, 809-819.	2.0	16
172	Does methotrexate influence COVID-19 infection? Case series and mechanistic data. Arthritis Research and Therapy, 2021, 23, 166.	3.5	16
173	Circadian rhythms of cellular immunity in rheumatoid arthritis: a hypothesis-generating study. Clinical and Experimental Rheumatology, 2015, 33, 34-43.	0.8	16
174	SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies. RMD Open, 2022, 8, e001934.	3.8	16
175	Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study. RMD Open, 2016, 2, e000228.	3.8	15
176	Ultra-low-dose CT detects synovitis in patients with suspected rheumatoid arthritis. Annals of the Rheumatic Diseases, 2019, 78, 31-35.	0.9	14
177	Canakinumab for treatment of cryopyrin-associated periodic syndrome. Expert Opinion on Biological Therapy, 2010, 10, 1631-1636.	3.1	13
178	Advances in diagnosis, treatment and definition of remission. Nature Reviews Rheumatology, 2012, 8, 65-66.	8.0	13
179	Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis. RMD Open, 2018, 4, e000602.	3.8	13
180	Fluorescence optical imaging for treatment monitoring in patients with early and active rheumatoid arthritis in a 1-year follow-up period. Arthritis Research and Therapy, 2019, 21, 209.	3.5	13

#	Article	IF	CITATIONS
181	Tocilizumab treatment for polyarteritis nodosa. Rheumatology, 2020, 59, e63-e65.	1.9	13
182	Macrophage activation syndrome in a patient with adult-onset Still's disease following first COVID-19 vaccination with BNT162b2. BMC Rheumatology, 2021, 5, 60.	1.6	13
183	Effectiveness and Safety of JAK Inhibitors in Autoinflammatory Diseases: A Systematic Review. Frontiers in Medicine, 0, 9, .	2.6	13
184	The proteasome $\hat{a} \in \tilde{~}$ victim or culprit in autoimmunity. Clinical Immunology, 2016, 172, 83-89.	3.2	12
185	Disentangling the effects of tocilizumab on neutrophil survival and function. Immunologic Research, 2016, 64, 665-676.	2.9	12
186	Observational study and brief analysis of diagnostic criteria in relapsing polychondritis. Rheumatology International, 2018, 38, 2095-2101.	3.0	12
187	2019 EULAR points to consider for the assessment of competences in rheumatology specialty training. Annals of the Rheumatic Diseases, 2021, 80, 65-70.	0.9	12
188	Fluorescence optical imaging: ready for prime time?. RMD Open, 2021, 7, e001497.	3.8	12
189	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET. Clinical and Experimental Rheumatology, 2022, 40, 3-11.	0.8	12
190	Novel autoantibodies against muscle-cell membrane proteins in patients with myositis. Arthritis and Rheumatism, 1996, 39, 1860-1868.	6.7	11
191	Hypogalactosylation of immunoglobulin G in rheumatoid arthritis: relationship to HLA-DRB1 shared epitope, anticitrullinated protein antibodies, rheumatoid factor, and correlation with inflammatory activity. Arthritis Research and Therapy, 2018, 20, 44.	3.5	11
192	A Randomized, Doubleâ€Blind Study Comparing Pharmacokinetics and Pharmacodynamics of Proposed Biosimilar ABP 798 With Rituximab Reference Product in Subjects With Moderate to Severe Rheumatoid Arthritis. Clinical Pharmacology in Drug Development, 2020, 9, 1003-1014.	1.6	11
193	Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitors. Rheumatology, 2021, 60, 4991-5001.	1.9	11
194	Gene Expression of Catalytic Proteasome Subunits and Resistance Toward Proteasome Inhibition of B Lymphocytes from Patients with Primary Sjögren Syndrome. Journal of Rheumatology, 2013, 40, 663-673.	2.0	10
195	Sustained Increase of 25-Hydroxyvitamin D Levels in Healthy Young Women during Wintertime after Three Suberythemal UV Irradiations—The MUVY Pilot Study. PLoS ONE, 2016, 11, e0159040.	2.5	10
196	Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab. RMD Open, 2017, 3, e000465.	3.8	10
197	Antiâ€interleukinâ€6 signalling therapy rebalances the disrupted cytokine production of B cells from patients with active rheumatoid arthritis. European Journal of Immunology, 2018, 48, 194-203.	2.9	10
198	Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3. RMD Open, 2021, 7, e001621.	3.8	10

#	Article	IF	CITATIONS
199	Fluorescence optical imaging for the detection of potential psoriatic arthritis in comparison to musculoskeletal ultrasound. JDDG - Journal of the German Society of Dermatology, 2019, 17, 913-921.	0.8	9
200	Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension. RMD Open, 2019, 5, e001017.	3.8	9
201	Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis. Clinical Rheumatology, 2020, 39, 3341-3352.	2.2	9
202	A Narrative Literature Review Comparing the Key Features of Musculoskeletal Involvement in Rheumatoid Arthritis and Systemic Lupus Erythematosus. Rheumatology and Therapy, 2022, 9, 781-802.	2.3	9
203	Trajectories of COVID-19 information in the Annals of the Rheumatic Diseases: the first months of the pandemic. Annals of the Rheumatic Diseases, 2021, 80, 26-30.	0.9	8
204	Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study). Rheumatology, 2021, 60, 5318-5328.	1.9	8
205	Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study. Annals of the Rheumatic Diseases, 2020, 79, 1023-1030.	0.9	8
206	Effects of treatment with etanercept versus methotrexate on sleep quality, fatigue and selected immune parameters in patients with active rheumatoid arthritis. Clinical and Experimental Rheumatology, 2016, 34, 848-856.	0.8	8
207	Characterisation of depressive symptoms in rheumatoid arthritis patients treated with tocilizumab during routine daily care. Clinical and Experimental Rheumatology, 2022, 40, 551-559.	0.8	8
208	Strategies using functional genomics in rheumatic diseases. Autoimmunity Reviews, 2004, 3, 541-549.	5.8	7
209	Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the ImPact ofResidual Inflammation Detected via Imaging TEchniques,Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab inClinical Remission Rheumatoid ArThritis (RA) patients (PREDICTRA). BMI Open, 2018, 8, e019007.	1.9	7
210	Role for antimalarials in the management of COVID-19. Current Opinion in Rheumatology, 2020, 32, 449-457.	4.3	7
211	Fibrinogen, factor XIII and $\hat{I}\pm2$ -antiplasmin genotypes are associated with inflammatory activity and anti-citrullinated protein antibodies. Thrombosis Research, 2020, 191, 90-96.	1.7	7
212	Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. Rheumatology and Therapy, 2022, 9, 243-263.	2.3	7
213	Tofacitinib for rheumatoid arthritis $\hat{a} \in $ Authors'reply. Lancet, The, 2013, 381, 1812-1813.	13.7	6
214	Response to: â€`Digital health: a new dimension in rheumatology patient care' by Kataria and Ravindran. Annals of the Rheumatic Diseases, 2019, 78, e104-e104.	0.9	6
215	Disease Activity Cutoff Values in Initiating Tumor Necrosis Factor Inhibitor Therapy in Ankylosing Spondylitis: A German GO-NICE Study Subanalysis. Journal of Rheumatology, 2020, 47, 35-41.	2.0	6
216	Clinical practice guidelines adherence, knowledge and awareness in rare and complex connective tissue diseases across Europe: results from the first ERN ReCONNET survey. RMD Open, 2020, 6, e001344.	3.8	6

#	Article	IF	CITATIONS
217	The citrullinated/native index of autoantibodies against hnRNP-DL predicts an individual "window of treatment success―in RA patients. Arthritis Research and Therapy, 2021, 23, 239.	3.5	6
218	Validation of the ASDAS with a quick quantitative CRP assay (ASDAS-Q) in patients with axial SpA: a prospective multicentre cross-sectional study. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210859.	2.7	6
219	Comparison of Photo Optical Imaging with Musculoskeletal Ultrasound and Clinical Examination in the Assessment of Inflammatory Activity in Proximal Interphalangeal Joints in Rheumatoid Arthritis and Osteoarthritis. Journal of Rheumatology, 2015, 42, 1595-1602.	2.0	5
220	A Human Osteochondral Tissue Model Mimicking Cytokine-Induced Key Features of Arthritis In Vitro. International Journal of Molecular Sciences, 2021, 22, 128.	4.1	5
221	Evaluation of SIGLEC1 in the diagnosis of suspected systemic lupus erythematosus. Rheumatology, 2022, 61, 3396-3400.	1.9	5
222	Methotrexate: what are the true risks of treatment?. Annals of the Rheumatic Diseases, 2020, 79, 1267-1268.	0.9	4
223	Sarilumab monotherapy <i>vs</i> sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis. Rheumatology, 2022, 61, 2596-2602.	1.9	4
224	The stress protein BiP is overexpressed and is a major B and T cell target in rheumatoid arthritis. Arthritis and Rheumatism, 2001, 44, 761-771.	6.7	4
225	Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis. Rheumatology and Therapy, 2022, 9, 191-206.	2.3	4
226	Follow-Up Comparison of Fluorescence Optical Imaging With Musculoskeletal Ultrasound for Early Detection of Psoriatic Arthritis. Frontiers in Medicine, 2022, 9, 845545.	2.6	4
227	Response to abatacept is associated with the inhibition of proteasome β1i expression in T cells of patients with rheumatoid arthritis. RMD Open, 2020, 6, e001248.	3.8	3
228	Outcomes and Findings of the International Rheumatoid Arthritis (RA) BIODAM Cohort for Validation of Soluble Biomarkers in RA. Journal of Rheumatology, 2020, 47, 796-808.	2.0	3
229	What will be the job of the rheumatologist in 2030?. Joint Bone Spine, 2020, 87, 525-527.	1.6	3
230	Johann Lucas Schoenlein (1793–1864): impact without publications. Annals of the Rheumatic Diseases, 2021, 80, 140-142.	0.9	3
231	Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3). Modern Rheumatology, 2022, 32, 273-283.	1.8	3
232	Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison. Clinical and Experimental Rheumatology, 2022, 40, 103-112.	0.8	3
233	The safety and effectiveness of tocilizumab in elderly patients with rheumatoid arthritis and in patients with comorbidities associated with age. Clinical and Experimental Rheumatology, 0, , .	0.8	3
234	Joachim Robert Kalden: one of the founders of autoimmunity research and immunotherapy. Annals of the Rheumatic Diseases, 2021, 80, 682-684.	0.9	2

#	Article	IF	CITATIONS
235	A new hypothesis of modular glucocorticoid actions: Steroid treatment of rheumatic diseases revisited. , 0, .		2
236	The role of upadacitinib in the treatment of moderate-to-severe active rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110476.	2.7	2
237	Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years. Modern Rheumatology, 2023, 33, 64-72.	1.8	2
238	Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure. Annals of the Rheumatic Diseases, 2022, 81, 944-950.	0.9	2
239	ICHIBAN, a non-interventional study evaluating tocilizumab long-term effectiveness and safety in patients with active rheumatoid arthritis. Clinical and Experimental Rheumatology, 2021, 39, 319-328.	0.8	2
240	Clinical images: Drummer's finger. Arthritis and Rheumatism, 1996, 39, 1258-1258.	6.7	1
241	A3.22â€Upregulated microRNA-182 Expression is Associated with Enhanced Conventional CD4+T Cell Proliferation in SLE. Annals of the Rheumatic Diseases, 2013, 72, A21.2-A21.	0.9	1
242	A3.26â€Proteasome inhibition with bortezomib in refractory SLE inhibits type I interferon and depletes plasma cells but does not inhibit their regeneration. Annals of the Rheumatic Diseases, 2014, 73, A52.2-A52.	0.9	1
243	05.08 Increased turnover of monocytes in patients with rheumatoid arthritis identified by transcriptome and cytometric profiling. , 2017, , .		1
244	Induction of proliferation and proâ€inflammatory cytokine production in rheumatoid arthritis peripheral blood mononuclear cells by a 65ÂKDa chondrocyte membraneâ€specific, constitutive target autoantigen (<scp>CH</scp> 65). International Journal of Rheumatic Diseases, 2017, 20, 1132-1141.	1.9	1
245	06.08â€Low-dose il-2 therapy in refractory sle: results from a single centre phase i/iia clinical trial. , 2017, , .		1
246	242 A phase III randomised placebo-controlled double-blind study of upadacitinib (ABT-494), a selective JAK-1 Inhibitor, in patients with active rheumatoid arthritis with inadequate response to conventional synthetic DMARDs. Rheumatology, 2018, 57, .	1.9	1
247	223 Sustained response in a phase III study of sarilumab plus nonbiologic disease modifying anti-rheumatic drugs in patients with active, moderate-to-severe rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Rheumatology, 2018, 57, .	1.9	1
248	081 Long-term safety with sarilumab plus conventional synthetic disease-modifying antirheumatic drugs and sarilumab monotherapy in rheumatoid arthritis: an integrated analysis with 9,000 patient-years of follow-up. Rheumatology, 2019, 58, .	1.9	1
249	O09 Safety profile of baricitinib for the treatment of RA up to 8.4 years: an updated integrated safety analysis. Rheumatology, 2021, 60, .	1.9	1
250	Train to target–ÂHow we might learn in the future. Joint Bone Spine, 2021, 88, 105126.	1.6	1
251	Is the fluorescence optical imaging (FOI) able to discriminate between rheumatoid arthritis patients with and without need of rituximab retherapy? A cohort study. BMJ Open, 2021, 11, e047713.	1.9	1
252	Serum cytokines and their predictive value in pulmonary involvement of systemic sclerosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2019, 36, 274-284.	0.2	1

#	Article	IF	CITATIONS
253	Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI). Clinical and Experimental Rheumatology, 2019, 37, 937-945.	0.8	1
254	ICHIBAN, a non-interventional study evaluating tocilizumab long-term effectiveness and safety in patients with active rheumatoid arthritis. Clinical and Experimental Rheumatology, 2021, 39, 319-328.	0.8	1
255	Evolving the comprehensive management of rheumatoid arthritis: identification of unmet needs and development of practical and educational tools. Clinical and Experimental Rheumatology, 2020, 38, 1056-1067.	0.8	1
256	Characterisation of depressive symptoms in rheumatoid arthritis patients treated with tocilizumab during routine daily care. Clinical and Experimental Rheumatology, 2021, , .	0.8	1
257	A review of the totality of evidence in the development of ABP 798, a rituximab biosimilar. Immunotherapy, 2022, , .	2.0	1
258	P196 Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 9.3 years: an updated integrated safety analysis. Rheumatology, 2022, 61, .	1.9	1
259	P220 Long-term safety profile of upadacitinib in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Rheumatology, 2022, 61, .	1.9	1
260	Reply: To the editor. Arthritis and Rheumatism, 1997, 40, 1185-1186.	6.7	0
261	Reply: Finger exostosis caused by drumming? Comment on the clinical image report by Buttgereit and Burmester. Arthritis and Rheumatism, 1997, 40, 1185-1186.	6.7	Ο
262	Protein array screening reveals IgA autoantigenicity patterns predicting anti-TNFÂ therapy response in rheumatoid arthritis patients. Annals of the Rheumatic Diseases, 2011, 70, A69-A70.	0.9	0
263	Increased levels of circulating Helios+ FoxP3+ natural regulatory T cells in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2011, 70, A50-A50.	0.9	0
264	Helios+ FoxP3+ naturally occurring regulatory T cells are peripherally expanded in active systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2012, 71, A41.2-A42.	0.9	0
265	077â€∫Immunogenicity of Subcutaneous and Intravenous Tocilizumab as Monotherapy or in Combination with Disease-Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis. Rheumatology, 0, , .	1.9	Ο
266	02.41â€New autoantigen (jktbp) part of stress granules closes the sensitivity gap in rheumatoid arthritis. , 2017, , .		0
267	02.34â€Enhanced conventional cd4 ⁺ t cell proliferation in sle is associated with up-regulation of microrna-182 and increased il-7 receptor signalling. , 2017, , .		0
268	07.17â€The mutated rna splicing protein hnrnp-a3 is a novel autoantigen in systemic rheumatic diseases a link to warburg effect in ra. , 2017, , .		0
269	06.12â€New protein array technology identifies rituximab treated non responder rheumatoid arthritis patients are generating a new autoantibody repertoire. , 2017, , .		0
270	06.14â€Proteasome inhibition with bortezomib in sle promotes therapeutically relevant depletion of short- and long-lived plasma cells but does not prevent their regeneration. , 2017, , .		0

#	Article	IF	CITATIONS
271	07.15â€New mutated peptidylarginine deiminase from porphyromonas gingivalis a target in early ra citrullinates major ra-autoantigens. , 2017, , .		0
272	P217 Efficacy and safety of filgotinib for patients with RA naÃ⁻ve to MTX therapy: FINCH3 primary outcome results. Rheumatology, 2020, 59, .	1.9	0
273	O36â€Low-dose IL-2 therapy modulates lymphocyte subsets that are involved in the regulation of germinal-centre reactions in patients with SLE. , 2020, , .		0
274	Granulomatous large vessel phlebitis in sarcoidosis. Rheumatology, 2021, 60, e432-e434.	1.9	0
275	The Effect of TNF-α Inhibitors on Nail Psoriasis and Psoriatic Arthritis—Real-World Data from Dermatology Practice. Journal of Personalized Medicine, 2021, 11, 1083.	2.5	0
276	Circulating Proteasome Level Is an Independent Prognostic Factor for Survival in Patients with Multiple Myeloma Blood, 2004, 104, 1486-1486.	1.4	0
277	Ultra-Low-Dose Computed Tomography Subtraction for the Detection of Synovitis in Patients with Inflammatory Joint Disease. Seminars in Musculoskeletal Radiology, 2019, 23, .	0.7	0
278	Publishing in 2@84. Annals of the Rheumatic Diseases, 2021, 80, 11-13.	0.9	0
279	Purinergic signaling in systemic sclerosis. Rheumatology, 2021, , .	1.9	0
280	Effectiveness and safety of anti-tumour necrosis factor therapy with certolizumab pegol observed in real-life rheumatoid arthritis patients in Germany: results from the non-interventional FαsT study. Clinical and Experimental Rheumatology, 2019, 37, 842-851.	0.8	0
281	The safety and effectiveness of tocilizumab in elderly patients with rheumatoid arthritis and in patients with comorbidities associated with age. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
282	Treatment of relapsing polychondritis: a systematic review Clinical and Experimental Rheumatology, 2022, , .	0.8	0
283	Blood biomarkers recommended for diagnosing and monitoring IgG4-related disease. Considerations from the ERN ReCONNET and collaborating partners Clinical and Experimental Rheumatology, 2022, , .	0.8	0
284	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET Clinical and Experimental Rheumatology, 2022, , .	0.8	0
285	Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison Clinical and Experimental Rheumatology, 2022, , .	0.8	0
286	OA01 Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Rheumatology, 2022, 61, .	1.9	0